Use of preneoplastic lesions in colon and liver in experimental oncology

Radiology and Oncology

Volumn 38, Issue 3, 2004, Pages

  Ehrlich, Veronika A ^a   Huber, Wolfgang ^a   Grasl Kraupp, Bettina ^a   Nersesyan, Armen ^a   Knasmüller, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Colonic neoplasms; Liver neoplasms; Preneoplastic lesions

Indexed keywords

5 HYDROXYMETHYLFURFURAL; ANTINEOPLASTIC AGENT; BETA CATENIN; BETA N ACETYLHEXOSAMINIDASE; CADHERIN; CARCINOEMBRYONIC ANTIGEN; CHENODEOXYCHOLIC ACID; CYCLINE; CYCLOOXYGENASE 2; DEXTRIN; ENZYME; FAT; FRUCTOSE; GLUTATHIONE TRANSFERASE; HEMIN; HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KI 67 ANTIGEN; MUCIN; PROGASTRIN; PROTEIN; SUCROSE; UVOMORULIN;

ABERRANT CRYPT FOCUS; ALTERED HEPATIC FOCUS; CANCER DIAGNOSIS; CANCER RESEARCH; CLINICAL STUDY; COLON CANCER; CPG ISLAND; EARLY CANCER; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; LIVER CANCER; MICROSATELLITE INSTABILITY; MOLECULAR MECHANICS; ONCOGENE; ONCOGENE K RAS; PRECANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 19644398044     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Williams G M. Chemically induced preneoplastic lesions in rodents as indicators of carcinogenic activity. MRC Sci Publ 1999 (146): 185-202.
2. Bannasch P. Preneoplastic lesions as end points in carcinogenicity testing. I. Hepatic preneoplasia. Carcinogenesis 1986; 7(5): 689-95.
3. Pitot H C. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990; 30: 465-500.
4. Williams G M. The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection. Toxicol Pathol 1989; 17(4 Pt 1): 663-72; 673-4.
5. Sakai H, Tsukamoto T, Yamamoto M, Kobayashi K, Yuasa H, Imai T et al. Distinction of carcinogens from mutagens by induction of liver cell foci in a model for detection of initiation activity. Cancer Lett 2002; 188(1-2): 33-8.
6. Williams G M, Tanaka T, Maeura Y. Dose-related inhibition of aflatoxin B1 induced hepatocarcinogenesis by the phenolic antioxidants, butylated hydroxyanisole and butylated hydroxytoluene. Carcinogenesis 1986; 7(7): 1043-50.
7. Maeura Y, Weisburger J H, Williams G M. Dose-dependent reduction of N-2-fluorenylacetamide-induced liver cancer and enhancement of bladder cancer in rats by butylated hydroxytoluene. Cancer Res 1984; 44(4): 1604-10.
8. Kassie F, Uhl M, Rabot S, Grasl-Kraupp B, Verkerk R, Kundi M et al. Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. Carcinogenesis 2003; 24(2): 255-61.
9. Kassie F, Rabot S, Uhl M, Huber W, Qin H M, Helma C et al. Chemoprotective effects of garden cress (Lepidium sativum) and its constituents towards 2-amino-3-methyl-imidazo[4/5-f]quinoline (IQ)-induced genotoxic effects and colonic preneoplastic lesions. Carcinogenesis 2002; 23(7): 1155-61.
10. Godlewski C E, Boyd J N, Sherman W K, Anderson J L, Stoewsand G S. Hepatic glutathione S-transferase activity and aflatoxin B1-induced enzyme altered foci in rats fed fractions of brussels sprouts. Cancer Lett 1985; 28(2): 151-7.
11. Uhl M, Kassie F, Rabot S, Grasl-Kraupp B, Chakraborty A, Laky B et al. Effect of common Brassica vegetables (Brussels sprouts and red cabbage) on the development of preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) in liver and colon of Fischer 344 rats. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802(1): 225-30.
12. Roebuck B D, Curphey T J, Li Y, Baumgartner K J, Bodreddigari S, Yan J et al. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 2003; 24(12): 1919-28.
13. Liu J, Yang C F, Wasser S, Shen H M, Tan C E, Ong C N. Protection of salvia miltiorrhiza against aflatoxin-B1-induced hepatocarcinogenesis in Fischer 344 rats dual mechanisms involved. Life Sci 2001; 69(3): 309-26.
14. Siess M H, Le Bon A M, Canivenc-Lavier M C, Suschetet M. Mechanisms involved in the chemoprevention of flavonoids. Biofactors 2000; 12(1-4): 193-9.
15. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA 1994; 91(21): 9995-9.
16. Emmelot P, Scherer E. The first relevant cell stage in rat liver carcinogenesis. A quantitative approach. Biochim Biophys Acta 1980; 605(2): 247-304.
17. Rabes H M, Szymkowiak R. Cell kinetics of hepatocytes during the preneoplastic period of diethylnitrosamine-induced liver carcinogenesis. Cancer Res 1979; 39(4): 1298-304.
18. Watanabe K, Williams G M. Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital: evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. J Natl Cancer Inst 1978; 61(5): 1311-4.
19. Pitot H C, Barsness L, Goldsworthy T, Kitagawa T. Biochemical characterisation of stages of hepato-carcinogenesis after a single dose of diethylnitrosamine. Nature 1978; 271(5644): 456-8.
20. Williams G M. Functional markers and growth behavior of preneoplastic hepatocytes. Cancer Res 1976; 36(7 PT 2): 2540-3.
21. Williams G M, Klaiber M, Parker S E, Farber E. Nature of early appearing, carcinogen-induced liver lesions to iron accumulation. J Natl Cancer Inst 1976; 57(1): 157-65.
22. Hirota N, Williams G M. Persistence and growth of rat liver neoplastic nodules following cessation of carcinogen exposure. J Natl Cancer Inst 1979; 63(5): 1257-65.
23. Schulte-Hermann R, Bursch W, Low-Baselli A, Wagner A, Grasl-Kraupp B. Apoptosis in the liver and its role in hepatocarcinogenesis. Cell Biol Toxicol 1997; 13(4-5): 339-48.
24. Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, Taper H, Huber W, Bursch W et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997; 25(4): 906-12.
25. Grasl-Kraupp B, Luebeck G, Wagner A, Low-Baselli A, de Gunst M, Waldhör T et al. Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis). Carcinogenesis 2000; 21(7): 1411-21.
26. Low-Baselli A, Hufnagl K, Parzefall W, Schulte-Hermann R, Grasl-Kraupp B. Initiated rat hepatocytes in primary culture: a novel tool to study alterations in growth control during the first stage of carcinogenesis. Carcinogenesis 2000; 21(1): 79-86.
27. Bird R P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37(2): 147-51.
28. Bird R P, McLellan E A, Bruce W R. Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Sun 1989; 8(1): 189-200.
29. Chang W W. Histogenesis of colon cancer in experimental animals. Scand J Gastroenterol Suppl 1984; 104: 27-43.
30. Cheng L, Lai M D. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol 2003; 9(12): 2642-9.
31. Roncucci L, Stamp D, Medline A, Cullen J B, Bruce W R. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22(3): 287-94.
32. Pretlow T P, Barrow B J, Ashton W S, O'Riordan M A, Pretlow T G, Jurcisek J A et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51(5): 1564-7.
33. Pretlow T P, O'Riordan M A, Spancake K M, Pretlow T G. Two types of putative preneoplastic lesions identified by hexosaminidase activity in whole-mounts of colons from F344 rats treated with carcinogen. Am J Pathol 1993; 142(6): 1695-700.
34. Boland C R, Martin M A, Goldstein I J. Lectin reactivities as intermediate biomarkers in premalignant colorectal epithelium. J Cell Biochem Suppl 1992; 16G: 103-9.
35. Pretlow T P, Roukhadze E V, O'Riordan M A, Chan J C, Amini S B, Stellato T A. Carcino-embryonic antigen in human colonic aberrant crypt foci. Gastroenterology 1994; 107(6): 1719-25.
36. Hardy R G, Tselepis C, Hoyland J, Wallis Y, Pretlow T P, Talbot I et al. Aberrant β-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002; 50(4): 513-9.
37. Hao X P, Pretlow T G, Rao J S, Pretlow T P. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001; 61(22): 8085-8.
38. Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of betacatenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 2000; 21(7): 1319-27.
39. Renehan A G, O'Dwyer S T, Haboubi N J, Potter C S. Early cellular events in colorectal carcinogenesis. Colorectal Dis 2002; 4(2): 76-89.
40. Uchida K, Kado S, Ando M, Nagata Y, Takagi A, Onoue M. A mucinous histochemical study on malignancy of aberrant crypt foci (ACF) in rat colon. J Vet Med Sci 2001; 63(2): 145-9.
41. Bara J, Forgue-Lafitte M E, Maurin N, Flejou J F, Zimber A. Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumour Biol 2003; 24(3): 109-15.
42. Miyanishi K, Takayama T, Ohi M, Hayashi T, Nobuoka A, Nakajima T et al. Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis. Gastroenterology 2001; 121(4): 865-74.
43. Stopera S A, Murphy L C, Bird R P. Evidence for a ras gene mutation in azoxymethane-induced colonie aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 1992; 13(11): 2081-5.
44. Losi L, Roncucci L, di Gregorio C, de Leon M P, Benhattar J. K-ras and p53 mutations in human colorectal aberrant crypt foci. J Pathol 1996; 178(3): 259-63.
45. Smith A J, Stern H S, Penner M, Hay K, Mitri A, Bapat B V et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994; 54(21): 5527-30.
46. Nascimbeni R, Villanacci V, Mariani P P, Di Betta E, Ghirardi M, Donato F et al. Aberrant crypt foci in the human colon: frequency and histologic patterns in patients with colorectal cancer or diverticular disease. Am J Surg Pathol 1999; 23(10): 1256-63.
47. Reitmair A H, Cai J C, Bjerknes M, Redston M, Cheng H, Pind M T et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 1996; 56(13): 2922-6.
48. Chan A O, Broaddus R R, Houlihan P S, Issa J P, Hamilton S R, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160(5): 1823-30.
49. Augenlicht L H, Richards C, Corner G, Pretlow T P. Evidence for genomic instability in human colonic aberrant crypt foci. Oncogene 1996; 12(8): 1767-72.
50. Hao X P, Willis J E, Pretlow T G, Rao J S, MacLennan G T, Talbot I C et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60(1): 18-21.
51. Corpet D E, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003; 12(5): 391-400.
52. Intiyot Y, Kinouchi T, Kataoka K, Arimochi H, Kuwahara T, Vinitketkumnuen U et al. Antimutagenicity of Murdannia loriformis in the Salmonella mutation assay and its inhibitory effects on azoxymethane-induced DNA methylation and aberrant crypt focus formation in male F344 rats. J Med Invest 2002; 49(1-2): 25-34.
53. Tudek B, Bird R P, Bruce W R. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 1989; 49(5): 1236-40.
54. Tanaka T, Barnes W S, Williams G M, Weisburger J H. Multipotential carcinogenicity of the fried food mutagen 2-amino-3-methylimidazo[4,5-f] quinoline in rats. Jpn J Cancer Res 1985; 76(7): 570-6.
55. Dashwood R H. Modulation of heterocyclic amine-induced mutagenicity and carcinogenicity: an 'A-to-Z' guide to chemopreventive agents, promoters, and transgenic models. Mutat Res 2002; 511(2): 89-112.
56. Schwab C E, Huber W W, Parzefall W, Hietsch G, Kassie F, Schulte-Hermann R et al. Search for compounds that inhibit the genotoxic and carcinogenic effects of heterocyclic aromatic amines. Crit Rev Toxicol 2000; 30(1): 1-69.
57. Corpet D E, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43(1): 1-21.
58. Zhang X M, Stamp D, Minkin S, Medline A, Corpet D E, Bruce W R et al. Promotion of aberrant crypt foci and cancer in rat colon by thermolyzed protein. J Natl Cancer Inst 1992; 84(13): 1026-30.
59. Zhang X M, Chan C C, Stamp D, Minkin S, Archer M C, Bruce W R. Initiation and promotion of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2- furaldehyde in thermolyzed sucrose. Carcinogenesis 1993; 14(4): 773-5.
60. Corpet D E, Stamp D, Medline A, Minkin S, Archer M C, Bruce W R. Promotion of colonic microadenoma growth in mice and rats fed cooked sugar or cooked casein and fat. Cancer Res 1990; 50(21): 6955-8.
61. Stamp D, Zhang X M, Medline A, Bruce W R, Archer M C. Sucrose enhancement of the early steps of colon carcinogenesis in mice. Carcinogenesis 1993; 14(4): 777-9.
62. Poulsen M, Molck A M, Thorup I, Breinholt V, Meyer O. The influence of simple sugars and starch given during pre- or post-initiation on aberrant crypt foci in rat colon. Cancer Lett 2001; 167(2): 135-43.
63. Cobb S, Wood T, Ceci J, Varro A, Velasco M, Singh P. Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice. Cancer 2004; 100(6): 1311-23.
64. Pierre F, Tache S, Petit C R, Van der Meer R, Corpet D E. Meat and cancer: haemoglobin and haemin in a low-calcium diet promote colorectal carcinogenesis at the aberrant crypt stage in rats. Carcinogenesis 2003; 24(10): 1683-90.
65. Ghia M, Mattioli F, Mereto E. A possible medium-term assay for detecting the effects of liver and colon carcinogens in rats. Cancer Lett 1996; 105(1): 71-5.
66. Sutherland L A, Bird R P. The effect of chenodeoxycholic acid on the development of aberrant crypt foci in the rat colon. Cancer Lett 1994; 76(2-3): 101-7.
67. De Flora S, Ramel C. Classification of mechanisms of inhibitors of mutagenesis and carcinogenesis. Basic Life Sci 1990; 52: 461-2.
68. Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319(9): 525-32.
69. Felton J S, Jaegerstad M, Knize M, Skog K, Wakabayashi K. Contents in Foods, Beverages and Tabacco. In: Nagao M, Sugimura T, editors. Food Borne Carcinogens - Heterocyclic Amines. Chichester: John Wiley & Sons Ltd; 2000. p. 31-73.
70. Ohgaki H. Carcinogenicity in Animals and Specific Organs - Rodents. In: Nagao M, Sugimura T, editors. Food Borne Carcinogens: Heterocyclic Amines. Chichester: John Wiley & Sons Ltd; 2000. p. 197-228.
71. Augustsson K, Steineck G. Cancer Risk Based on Epidemiological Studies. In: Nagao M, Sugimura T, editors. Food Borne Carcinogens - Heterocyclic Amines. Chichester: John Wiley & Sons Ltd.; 2000. p. 332-348.
72. Kassie F, Sundermann V M, Edenharder R, Platt K L, Darroudi F, Lhoste E et al. Development and application of test methods for the detection of dietary constituents which protect against heterocyclic aromatic amines. Mutat Res 2003; 523-524: 183-92.
73. Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K et al. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003; 24(1): 107-11.
74. Magnuson B A, Carr I, Bird R P. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993; 53(19): 4499-504.
75. Magnuson B A, Bird R P. Reduction of aberrant crypt foci induced in rat colon with azoxymethane or methylnitrosourea by feeding cholic acid. Cancer Lett 1993; 68(1): 15-23.
76. Steele V E, Pereira M A, Sigman C C, Kelloff G J. Cancer chemoprevention agent development strategies for genistein. J Nutr 1995; 125(3 Suppl): 713S-716S.
77. Pereira M A, Barnes L H, Rassman V L, Kelloff G V, Steele V E. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994; 15(5): 1049-54.
78. Rao C V, Wang C X, Simi B, Lubet R, Kelloff G, Steele V et al. Enhancement of experimental colon cancer by genistein. Cancer Res 1997; 57(17): 3717-22.
79. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M et al. Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000; 60(13): 3323-7.
80. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K et al. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61(5): 1874-8.
81. Mori H, Yamada Y, Hirose Y, Kuno T, Katayama M, Sakata K et al. Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker. Eur J Cancer Prev 2002; 11 Suppl 2: S71-5.
82. Morin P J, Sparks A B, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275(5307): 1787-90.
83. Pretlow T P, Bird R P. Correspondence re: Y. Yamada et al., frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000, 60: 3323-3327.
84. Femia A P, Dolara P, Caderni G. Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis 2004; 25(2): 277-81.
85. Knasmuller S, Steinkellner H, Majer B J, Nobis E C, Scharf G, Kassie F. Search for dietary antimutagens and anticarcinogens: methodological aspects and extrapolation problems. Food Chem Toxicol 2002; 40(8): 1051-62.